2. Search Result
Search Result
Results for "

Endotoxin inhibitor

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

3

Biochemical Assay Reagents

7

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3912A
    Endotoxin inhibitor TFA

    		Interleukin Related Infection
    Endotoxin inhibitor TFA is a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor TFA inhibits the febrile response to LPS with very low toxicity and lethality .
    Endotoxin inhibitor TFA
  • HY-110133
    JTE-607
    3 Publications Verification

    		 Interleukin Related Inflammation/Immunology
    JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively . Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607 .
    JTE-607
  • HY-135042
    CAY10614
    1 Publications Verification

    		 Toll-like Receptor (TLR) Neurological Disease
    CAY10614 is a potent TLR4 antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC50 of 1.675 μM. CAY10614 can improve survival of mice in lethal endotoxin shock model .
    CAY10614
  • HY-149179
    Polymyxin B
    Maximum Cited Publications
    13 Publications Verification

    		 Bacterial Antibiotic Infection
    Polymyxin B is an antibiotic. Polymyxin B inhibits Gram-negative infections by binding to the LPS of the bacterial wall with high affinity. Polymyxin B neutralizes the effect of endotoxin. Polymyxin B induces bacterial death by increasing its permeability. Polymyxin B is used in endotoxemia research .
    Polymyxin B
  • HY-P3496
    Pep19-2.5

    		Pyroptosis Inflammation/Immunology
    Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis .
    Pep19-2.5
  • HY-P3912
    Endotoxin inhibitor

    		COX Interleukin Related Infection
    Endotoxin inhibitor a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor inhibits the febrile response to LPS with very low toxicity and lethality .
    Endotoxin inhibitor
  • HY-110133A
    JTE-607 free base

    		Interleukin Related Inflammation/Immunology
    JTE-607 free base, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 free base inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively . Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607 free base .
    JTE-607 free base
  • HY-137418
    2-MeS-ATP

    2-Methylthio-ATP

    		 P2Y Receptor Others Inflammation/Immunology
    2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases .
    2-MeS-ATP
  • HY-P1694
    B4148

    		Bradykinin Receptor Cardiovascular Disease
    B4148 is a selective competitive bradykinin (BK) antagonist that significantly inhibits BK-induced hypotension in rats. In a rat model of endotoxin shock induced by Escherichia coli lipopolysaccharide, B4148 significantly attenuated the decrease in mean arterial blood pressure compared with the control group .
    B4148
  • HY-19101
    ONO-3307

    		Kallikrein Cardiovascular Disease
    ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases .
    ONO-3307
  • HY-P2170
    XMP-629

    XOMA-629

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    XMP-629 (XOMA-629), a cationic α-helical peptide, is a potent endotoxin inhibitor. XMP-629 exhibits broad-spectrum antimicrobial activity via an immunomodulatory mechanism. XOMA 629 has antimicrobial activity against Propionibacterium acnes, Staphylococcus aureus and Streptococcus pyogenesand .
    XMP-629
  • HY-19126
    CL-184005

    		Platelet-activating Factor Receptor (PAFR) Infection Cardiovascular Disease
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-W342458
    Betamethasone 17-Propionate

    		Biochemical Assay Reagents Others
    Betamethasone 17-Propionate is a compound used to study its effects on endotoxin-induced uveitis in rats. It has the activity of inhibiting the infiltration of cells into the aqueous humor in endotoxin-induced uveitis by eye drops and systemic administration at a certain dose. However, its inhibitory effect is relatively weak compared with some other compounds. At the same time, the dose for systemic administration is 1mg/kg. In addition, Betamethasone 17-Propionate has a weaker inhibitory effect on the release of IL-8 from rat peritoneal exudate cells in an in vitro interleukin-8 (IL-8) release assay than betamethasone. Moreover, the simultaneous addition of betamethasone dipropionate and betamethasone 17-Propionate reduces the inhibitory effect of betamethasone on cell infiltration and IL-1β gene expression.
    Betamethasone 17-Propionate
  • HY-P1698
    Reltecimod

    AB-103

    		 Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-E70005H
    Collagenase, Type VIII

    		Proteasome Cardiovascular Disease
    Collagenase, Type VIII is a mixed enzyme derived from Clostridium histolyticum that contains collagenase, a nonspecific protease, and a clostripain. Collagenase, Type VIII can hydrolyze Type VIII collagen and may be used to study the formation of atherosclerosis. Type VIII collagen is a regulator of endothelial cell differentiation and angiogenesis, a substrate for cell adhesion and migration such as smooth muscle cells, and may accumulate in atherosclerosis. After endotoxin activates the expression of Collagenase, Type VIII, it can reduce the production of Type VIII collagen and has the potential to inhibit atherosclerosis .
    Collagenase, Type VIII
  • HY-P1698B
    Reltecimod TFA

    AB-103 TFA

    		 Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-D1056I
    Lipopolysaccharides, from Akkermansia muciniphila

    LPS, from Akkermansia muciniphila

    		 Biochemical Assay Reagents Others
    Lipopolysaccharides, from Akkermansia muciniphila (LPS, from Akkermansia muciniphila) are lipopolysaccharide endotoxins derived from Akkermansia muciniphila and are TLR-4 activators. Unlike typical LPS, Lipopolysaccharides, from Akkermansia muciniphila are R-type LPS or lipooligosaccharides (LOS), lacking the O-antigen domain and consisting only of a core oligosaccharide and a lipid A. Lipopolysaccharides, from Akkermansia muciniphila can activate TLR4 and TLR2, and may inhibit the TLR4/NF-κB pathway, thereby alleviating LPS-induced acute kidney injury .
    Lipopolysaccharides, from Akkermansia muciniphila
  • HY-D1056B3
    Lipopolysaccharides, from Klebsiella pneumoniae

    LPS, from bacterial (Klebsiella pneumoniae)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .
    Lipopolysaccharides, from Klebsiella pneumoniae
  • HY-N7075
    Inulin
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease Cancer
    Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
    Inulin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: